{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:27:04Z","timestamp":1792092424148,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>Most patient-reported outcome measures for narcolepsy focus on excessive daytime sleepiness or do not focus on specific disease impacts (e.g. cataplexy, cognitive difficulties, fatigue, daily function). The Functional Impacts of Narcolepsy Instrument (FINI) was developed to measure key functional impacts in people with narcolepsy type 1 and 2 (NT1\/NT2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The instrument was developed separately in NT1\/NT2 populations with input from patients, clinical experts experienced in narcolepsy management, and clinical outcome scientists. Development included: patient experience interview studies informing item development; item development including de novo items, and modified\/original items from the Patient-Reported Outcomes Measurement Information System (PROMIS) library; two waves of patient-debriefing interviews testing initial\/modified item drafts; determination of scale structure using exploratory factor and Rasch analyses, and confirmatory factor analyses for NT2; consensus meetings between clinical sleep experts\/clinical outcome experts to finalize the FINI draft items and structure with a 7-day recall period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final FINI for NT1 had 28 items within six independent domains: Tiredness, Cognitive Functioning, Cataplexy, Social Activities, Everyday Activities, and Everyday Responsibilities. The final NT2 version (FINI-NT2) included the same items excluding the Cataplexy domain (23 items). Final FINI and FINI-NT2 items demonstrated good content validity and covered the main impacts of NT1 and NT2, respectively, as confirmed by patient interviews, exploratory\/confirmatory factor analyses, and Rasch analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The novel FINI assesses key functional impacts of narcolepsy in people with NT1\/NT2 for use across clinical settings, and adds to the number of existing clinical outcome assessments for central disorders of hypersomnolence.<\/jats:p>\n                    <jats:p>Statement of Significance People with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) often experience impacts on their daily life, such as cognitive difficulties, fatigue, and impaired work\/school responsibilities, leading to decreased quality of life. Despite these recognized challenges, there remains a need for an additional tool that measures functional outcomes and complements existing narcolepsy symptom, severity, and impacts assessments. The Functional Impacts of Narcolepsy Instrument (FINI) was developed to evaluate functional impacts of narcolepsy that are important and meaningful to people living with NT1 (FINI) and NT2 (FINI-NT2). The instrument offers a patient-centered outcome measure for assessing narcolepsy impacts and treatment benefits related to changes in functional outcomes that can be used in both the clinical trial setting and clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsag127","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:30:00Z","timestamp":1778585400000},"source":"Crossref","is-referenced-by-count":3,"title":["Development and content validity of the Functional Impacts of Narcolepsy Instrument: a novel patient-reported outcome measure for narcolepsy type 1 and type 2"],"prefix":"10.1093","volume":"49","author":[{"given":"Yulia","family":"Savva","sequence":"first","affiliation":[{"name":"Global Medical Affairs \u2013 Neuroscience, Takeda Development Center Americas, Inc. , Cambridge, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Romero","sequence":"additional","affiliation":[{"name":"Global Medical Affairs \u2013 Neuroscience, Takeda Development Center Americas, Inc. , Cambridge, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crawford","sequence":"additional","affiliation":[{"name":"Global Medical Affairs \u2013 Neuroscience, Takeda Development Center Americas, Inc. , Cambridge, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Howerter","sequence":"additional","affiliation":[{"name":"Prospective Studies, Clinical Outcomes Solutions , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McPherson","sequence":"additional","affiliation":[{"name":"Qualitative Science, Clinical Outcomes Solutions, Folkestone, Kent ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Doll","sequence":"additional","affiliation":[{"name":"Quantitative Science, Clinical Outcomes Solutions , Folkestone, Kent,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Symonds","sequence":"additional","affiliation":[{"name":"Qualitative Science, Clinical Outcomes Solutions, Folkestone, Kent ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Swick","sequence":"additional","affiliation":[{"name":"Global Medical Affairs \u2013 Neuroscience, Takeda Development Center Americas, Inc. , Cambridge, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-6506","authenticated-orcid":false,"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[{"name":"Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, University of Montpellier , Montpellier ,","place":["France"]},{"name":"Institute of Neurosciences of Montpellier, INSERM, University of Montpellier , Montpellier,","place":["France"]},{"name":"National Reference Network for Narcolepsy , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"27","key":"2026081400271481600_ref1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2026081400271481600_ref2","first-page":"233","article-title":"The medical and economic burden of narcolepsy: implications for managed care","volume":"10","author":"Thorpy","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"2026081400271481600_ref3","doi-asserted-by":"publisher","first-page":"zsaa044","DOI":"10.1093\/sleep\/zsaa044","article-title":"To split or to lump? Classifying the central disorders of hypersomnolence","volume":"43","author":"Fronczek","year":"2020","journal-title":"Sleep."},{"issue":"3","key":"2026081400271481600_ref4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5664\/jcsm.5594","article-title":"The humanistic and economic burden of narcolepsy","volume":"12","author":"Flores","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"2026081400271481600_ref5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp.2008.161588","article-title":"Psychological health in central hypersomnias: the French Harmony study","volume":"80","author":"Dauvilliers","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2026081400271481600_ref6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sleep.2010.07.008","article-title":"A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy","volume":"12","author":"Vignatelli","year":"2011","journal-title":"Sleep Med"},{"issue":"5","key":"2026081400271481600_ref7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.sleep.2004.04.003","article-title":"Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey","volume":"5","author":"Vignatelli","year":"2004","journal-title":"Sleep Med"},{"key":"2026081400271481600_ref8","author":"US Food and Drug Administration"},{"issue":"3","key":"2026081400271481600_ref9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy","volume":"13","author":"Maski","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"2026081400271481600_ref10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep."},{"issue":"6","key":"2026081400271481600_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa009","article-title":"Narcolepsy severity scale: a reliable tool assessing symptom severity and consequences","volume":"43","author":"Dauvilliers","year":"2020","journal-title":"Sleep."},{"issue":"14","key":"2026081400271481600_ref12","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/WNL.0000000000003787","article-title":"Measurement of narcolepsy symptoms: the Narcolepsy Severity Scale","volume":"88","author":"Dauvilliers","year":"2017","journal-title":"Neurology."},{"key":"2026081400271481600_ref13","doi-asserted-by":"publisher","first-page":"106589","DOI":"10.1016\/j.sleep.2025.106589","article-title":"Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation","volume":"133","author":"Bijlenga","year":"2025","journal-title":"Sleep Med"},{"issue":"10","key":"2026081400271481600_ref14","first-page":"835","article-title":"An instrument to measure functional status outcomes for disorders of excessive sleepiness","volume":"20","author":"Weaver","year":"1997","journal-title":"Sleep."},{"key":"2026081400271481600_ref15","author":"EuroQol Research Foundation","year":"2019"},{"issue":"5","key":"2026081400271481600_ref16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"key":"2026081400271481600_ref17","author":"US Food and Drug Administration"},{"issue":"1","key":"2026081400271481600_ref18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s41687-020-00248-z","article-title":"Good practices for the translation, cultural adaptation, and linguistic validation of clinician-reported outcome, observer-reported outcome, and performance outcome measures","volume":"4","author":"McKown","year":"2020","journal-title":"J Patient Rep Outcomes"},{"issue":"4","key":"2026081400271481600_ref19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","article-title":"Code saturation versus meaning saturation: how many interviews are enough?","volume":"27","author":"Hennink","year":"2017","journal-title":"Qual Health Res"},{"issue":"7","key":"2026081400271481600_ref20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.9734\/ajeba\/2024\/v24i71430","article-title":"Fit indices in structural equation modeling and confirmatory factor analysis: reporting guidelines","volume":"24","author":"Sathyanarayana","year":"2024","journal-title":"Asian J Econ Bus Account"},{"key":"2026081400271481600_ref21","volume-title":"Evaluating cutoff criteria of model fit indices for latent variable models with binary and continuous outcomes [dissertation]","author":"Yu","year":"2002"},{"issue":"9","key":"2026081400271481600_ref22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","article-title":"Disrupted nighttime sleep in narcolepsy","volume":"9","author":"Roth","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"2026081400271481600_ref23","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","edition":"3rd edition"},{"key":"2026081400271481600_ref24","volume-title":"SF-36 Health Survey Manual and Interpretation Guide. New England Medical Center, the Health Institute","author":"Ware","year":"1993"},{"issue":"4","key":"2026081400271481600_ref25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach","volume":"10","author":"Hoddes","year":"1973","journal-title":"Psychophysiology."},{"issue":"4","key":"2026081400271481600_ref26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"issue":"2","key":"2026081400271481600_ref27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"2026081400271481600_ref28","author":"US Food and Drug Administration"},{"key":"2026081400271481600_ref29","author":"National Highway Traffic Safety Administration"}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsag127\/68280111\/zsag127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/8\/zsag127\/68280111\/zsag127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/8\/zsag127\/68280111\/zsag127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:27:25Z","timestamp":1786681645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsag127\/8677392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsag127","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,13]]},"article-number":"zsag127"}}